The University of California San Francisco Comprehensive Cancer Center is an NCI-designed matrix center conducting a wide range of inter-disciplinary research in the areas of laboratory, clinical and population sciences integrating the activities of 223 members working at 4 major campus and hospital locations. Its goals are to: (1) support cancer research of the highest possible quality, in the areas of laboratory, clinical and population sciences; (2) develop patient outreach and education programs to increase the value of the Center to the local community; (3) promote and develop first-class care for cancer patient in our affiliated hospitals; and (4) create an integrated community of investigators dedicated to the shared goal of translating innovative science into improved clinical care. These goals are accomplished through the following 11 Programs and 12 Shared Resources: ? ? Programs Shared Resources ? Breast Cancer Laboratory for Cell Analysis ? Neurologic Oncology Genome Analysis ? Cancer & Immunity Array ? Prostate Cancer Tissue ? Society, Diversity & Disparities Immunohistochemistry and Molecular Pathology ? Pancreas Cancer Transgenic/Targeted Mutagenesis ? Hematopoietic Malignancies Informatics ? Pediatric Malignancies Mouse Pathology ? Cell Cycling and Signaling Preclinical Therapeutics ? Cancer Genetics Mass Spectrometry ? Tobacco Control Biostatistics ? Clinical Research Support Services ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA082103-10
Application #
7500295
Study Section
Subcommittee G - Education (NCI)
Program Officer
Marino, Michael A
Project Start
1999-08-05
Project End
2012-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
10
Fiscal Year
2008
Total Cost
$7,585,971
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Sannino, Sara; Guerriero, Christopher J; Sabnis, Amit J et al. (2018) Compensatory increases of select proteostasis networks after Hsp70 inhibition in cancer cells. J Cell Sci 131:
Lam, Christine; Ferguson, Ian D; Mariano, Margarette C et al. (2018) Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Haematologica 103:1218-1228
Truillet, Charles; Parker, Matthew F L; Huynh, Loc T et al. (2018) Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget 9:20399-20408
Phillips, Kathryn A; Trosman, Julia R; Deverka, Patricia A et al. (2018) Insurance coverage for genomic tests. Science 360:278-279
Phillips, Kathryn A (2018) Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA 319:2379-2380
Puri, Sapna; Roy, Nilotpal; Russ, Holger A et al. (2018) Replication confers ? cell immaturity. Nat Commun 9:485
An, Zhenyi; Aksoy, Ozlem; Zheng, Tina et al. (2018) Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene 37:1561-1575
Behr, Spencer C; Villanueva-Meyer, Javier E; Li, Yan et al. (2018) Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight 3:
Rubenstein, James L; Geng, Huimin; Fraser, Eleanor J et al. (2018) Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv 2:1595-1607
An, Zhenyi; Knobbe-Thomsen, Christiane B; Wan, Xiaohua et al. (2018) EGFR Cooperates with EGFRvIII to Recruit Macrophages in Glioblastoma. Cancer Res 78:6785-6794

Showing the most recent 10 out of 192 publications